pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
Rapcabtagene autoleucel
Phase 2 · mab · ANCA Associated Vasculitis (AAV)
Rapcabtagene autoleucel for ANCA Associated Vasculitis (AAV) is a Phase 2 program (mab) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code CYTB323I12201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Modality
- mab
- Indication
- ANCA Associated Vasculitis (AAV)
- Status
- active
- Trials
- 1